Abstract
The control of osteoblast/osteoclast cross-talk is crucial in the bone remodelling process
and provides a target mechanism in the development of drugs for bone metabolic diseases.
Osteoprotegerin is a key molecule in this biosignalling pathway as it inhibits osteoclastogenesis
and osteoclast activation to prevent run-away bone resorption. This work reports the synthesis of a
known osteoprotegerin peptide analogue, YCEIEFCYLIR (OP3-4), and its tagging with a gadolinium
chelate, a standard contrast agent for magnetic resonance imaging. The resulting contrast agent
allows the simultaneous imaging and treatment of metabolic bone diseases. The gadolinium-tagged
peptide was successfully synthesised, showing unaltered magnetic resonance imaging contrast
agent properties, a lack of cytotoxicity, and dose-dependent inhibition of osteoclastogenesis in vitro.
These findings pave the way toward the development of biospecific and bioactive contrast agents
for the early diagnosis, treatment, and follow up of metabolic bone diseases such as osteoporosis
and osteosarcoma.
and provides a target mechanism in the development of drugs for bone metabolic diseases.
Osteoprotegerin is a key molecule in this biosignalling pathway as it inhibits osteoclastogenesis
and osteoclast activation to prevent run-away bone resorption. This work reports the synthesis of a
known osteoprotegerin peptide analogue, YCEIEFCYLIR (OP3-4), and its tagging with a gadolinium
chelate, a standard contrast agent for magnetic resonance imaging. The resulting contrast agent
allows the simultaneous imaging and treatment of metabolic bone diseases. The gadolinium-tagged
peptide was successfully synthesised, showing unaltered magnetic resonance imaging contrast
agent properties, a lack of cytotoxicity, and dose-dependent inhibition of osteoclastogenesis in vitro.
These findings pave the way toward the development of biospecific and bioactive contrast agents
for the early diagnosis, treatment, and follow up of metabolic bone diseases such as osteoporosis
and osteosarcoma.
| Original language | English |
|---|---|
| Pages (from-to) | 1-15 |
| Number of pages | 15 |
| Journal | Nanomaterials |
| Volume | 8 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - 2 Jun 2018 |
Keywords
- osteoporosis
- magnetic resonance imaging
- contrast agents
Fingerprint
Dive into the research topics of 'Gadolinium Tagged Osteoprotegerin-Mimicking Peptide: A Novel Magnetic Resonance Imaging Biospecific Contrast Agent for the Inhibition of Osteoclastogenesis and Osteoclast Activity'. Together they form a unique fingerprint.Profiles
-
Matteo Santin
- School of Applied Sciences - Professor of Tissue Regeneration
- Centre for Precision Health and Translational Medicine
- Centre for Arts and Wellbeing
- Centre for Regenerative Medicine and Devices - Director
Person: Academic